<DOC>
	<DOCNO>NCT00318136</DOCNO>
	<brief_summary>This open-label , single-arm , multicenter pilot study evaluate safety efficacy carboplatin/paclitaxel+bevacizumab subject locally advance ( Stage IIIb pleural effusion/pericardial effusion ) , Stage IV , recurrent squamous Non-Small Cell Lung Cancer ( NSCLC ) receive prior systemic therapy metastatic disease .</brief_summary>
	<brief_title>A Study Bevacizumab Plus Carboplatin Paclitaxel Subjects With Advanced , Previously Untreated , Squamous Non-Small Cell Lung Cancer ( BRIDGE )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Signed Informed Consent Form ( ) At least 18 year age Advanced histologically cytologically confirm predominant squamous NSCLC Subjects treat brain metastasis eligible evidence progression hemorrhage treatment brain metastasis/metastases Prior treatment CNS disease deem appropriate treating physician ECOG performance status 0 , 1 , 2 Measurable evaluable disease Use accept effective method contraception ( hormonal barrier method , abstinence ) prior study entry duration study ( woman childbearing potential sexually active men ) Prior chemotherapy metastatic disease Adjuvant chemotherapy prior combine modality therapy ( chemotherapy plus radiotherapy ) &lt; 6 month elapse completion treatment Day 1 , Cycle 1 Extrathoracic metastasis sit disease Active malignancy lung cancer Current , recent , planned participation another experimental drug study Untreated brain metastasis Presence intrathoracic lesion ( ) cavitation Gross hemoptysis within 3 month prior Day 1 In opinion investigator local radiologist , evidence tumor extend lumen major blood vessel Inadequately control hypertension Unstable angina NYHA Grade II great CHF Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 1 Myocardial infarction within 6 month prior Day 1 , Cycle 1 Stroke within 6 month prior Day 1 , Cycle 1 Active symptomatic peripheral vascular disease within 6 month prior Day 1 , Cycle 1 History significant vascular disease Evidence bleed diathesis coagulopathy Current , ongoing treatment fulldose warfarin equivalent Current recent use aspirin ( &gt; 325 mg/day ) Known hypersensitivity component bevacizumab Serious , nonhealing wound , ulcer , bone fracture UPC ratio â‰¥ 1.0 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 , Cycle 1 , anticipation need major surgical procedure course study Pregnancy lactation Inadequate organ function Any medical condition ( include mental illness substance abuse ) deem clinician likely interfere subject 's ability provide inform consent , cooperate , participate study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>BRIDGE</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Avastin</keyword>
</DOC>